PD-1 and PD-L 1 inhibitors

Nov 05, 2026

After KEYTRUDA: How PD-1 and PD-L1 Inhibitors Are Being Redesigned for a Post-Patent Era

Jun 13, 2025

Navigating the Loss of Exclusivity: Big Pharma’s New Playbook

Jun 14, 2024

OPDIVO vs. KEYTRUDA: The Battle for Japan’s PD-1 Inhibitor Market Dominance

May 31, 2024

The Journey of PD-(L)1 Inhibitors: Milestones and Breakthroughs

Nov 06, 2023

Coherus and Junshi’s Loqtorzi: First-ever Chinese PD-1 Inhibitor and Nasopharyngeal Carcinoma Treatment

Feb 24, 2023

Top 10 Expected Oncology Drug Launches in 2023

Dec 02, 2022

PD-1 and PD-L1 Inhibitors: Will They Dominate Over Conventional Cancer Therapies?

Apr 04, 2022

LAG 3: A Promising Next Generation Cancer Immunotherapy

Mar 29, 2022

Sanofi’s Rare Disease Drug Xenpozyme’ Approval; FDA Approves Novartis’ Pluvicto; AstraZeneca’s Imfinzi Trial Result; FDA’s Green Signal to Argenx’ Vyvgart; ViiV Healthcare and J&J’s HIV Treatment Cabenuva; UCB’s FINTEPLA Approval; Cullinan’s Update for CLN-081; MEI Pharma & Kyowa’s Zandelisib Approval

Newsletter/Whitepaper